- Home
- EMIS vs UNCY Comparison
EMIS vs UNCY Comparison
Compare EMIS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.02
HOLD
Current Price
$6.22
Company Overview
Basic Information| Metric | EMIS | UNCY |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 141.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EMIS | UNCY |
|---|---|---|
| Price | $10.02 | $6.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 17.6K | ★ 669.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $3.71 |
| 52 Week High | $11.11 | $11.00 |
Technical Indicators
Market Signals| Indicator | EMIS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 48.17 |
| Support Level | $10.03 | $5.98 |
| Resistance Level | $10.08 | $6.78 |
| Average True Range (ATR) | 0.01 | 0.46 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 22.22 | 29.71 |
Price Performance
Historical Comparison EMIS
UNCY
About EMIS Emmis Acquisition Corp. Class A Ordinary Shares
Emmis Acquisition Corp is a blank check company.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.